RT Journal Article
SR Electronic
T1 Optimal disease surveillance with graph-based Active Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.21.24309284
DO 10.1101/2024.06.21.24309284
A1 Tsui, Joseph L.-H.
A1 Zhang, Mengyan
A1 Sambaturu, Prathyush
A1 Busch-Moreno, Simon
A1 Suchard, Marc A.
A1 Pybus, Oliver G.
A1 Flaxman, Seth
A1 Semenova, Elizaveta
A1 Kraemera, Moritz U. G.
YR 2024
UL http://medrxiv.org/content/early/2024/06/21/2024.06.21.24309284.abstract
AB Tracking the spread of emerging pathogens is critical to the design of timely and effective public health responses. Policymakers face the challenge of allocating finite resources for testing and surveillance across locations, with the goal of maximising the information obtained about the underlying trends in prevalence and incidence. We model this decision-making process as an iterative node classification problem on an undirected and unweighted graph, in which nodes represent locations and edges represent movement of infectious agents among them. To begin, a single node is randomly selected for testing and determined to be either infected or uninfected. Test feedback is then used to update estimates of the probability of unobserved nodes being infected and to inform the selection of nodes for testing at the next iterations, until a certain resource budget is exhausted. Using this framework we evaluate and compare the performance of previously developed Active Learning policies, including node-entropy and Bayesian Active Learning by Disagreement. We explore the performance of these policies under different outbreak scenarios using simulated outbreaks on both synthetic and empirical networks. Further, we propose a novel policy that considers the distance-weighted average entropy of infection predictions among the neighbours of each candidate node. Our proposed policy outperforms existing ones in most outbreak scenarios, leading to a reduction in the number of tests required to achieve a certain predictive accuracy. Our findings could inform the design of cost-effective surveillance strategies for emerging and endemic pathogens, and reduce the uncertainties associated with early risk assessments in resource-constrained situations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.U.G.K. acknowledges funding from The Rockefeller Foundation, Google.org, the Oxford Martin School Pandemic Genomics programme (also O.G.P. & J.L.-H.T.), European Union's Horizon Europe programme projects MOOD (#874850) and E4Warning (#101086640), the John Fell Fund, a Branco Weiss Fellowship and Wellcome Trust grants 225288/Z/22/Z, 226052/Z/22/Z & 228186/Z/23/Z, United Kingdom Research and Innovation (#APP8583) and the Medical Research Foundation (MRF-RG-ICCH-2022-100069). J.L.-H.T. is supported by a Yeotown Scholarship from New College, University of Oxford. The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission or the other funders. E.S. acknowledges support in part by the AI2050 program at Schmidt Futures (Grant [G-22-64476]). M.A.S. is supported in part through the US National Institutes of Health grant R01 AI153044. S.F. and M.Z. acknowledge the EPSRC (EP/V002910/2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be made available online at https://github.com/joetsui1994/optimal-disease-surveillance-AL